Chronic postrheumatic arthropathy [Jaccoud]

M13_POSTRHEU

No definition available.

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps	FinnGen
Phenotype data	520210
1. Apply sex-specific rule None	520210
2. Check conditions None	520210
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — M12.0 Hospital discharge: ICD-8 — 7125 Cause of death: ICD-10 — M12.0 Cause of death: ICD-8 — 7125 2 out of 7 registries used, show all original rules.	49
4. Check minimum number of events None	49
5. Include endpoints None	49
6. Filter based on genotype QC (FinnGen only)	49

Control definitions (FinnGen only)

Control exclude: M13_ARTHROPATHIES

Extra metadata

Level in the ICD hierarchy: 4
First used in FinnGen datafreeze: DF2
Parent code in ICD-10: M12
Name in latin: Arthropathia postrheumatica chronica (Jaccoud)

NAME	M13_POSTRHEU
CONTROL_EXCLUDE	M13_ARTHROPATHIES
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	M120
HD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_8	7125
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	M120
COD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_8	7125
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Chronic postrheumatic arthropathy [Jaccoud] based on the number of shared cases.

Similar with more cases:

Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	427	288	134
Only index persons	340	231	109
Unadjusted period prevalence (%)
Whole population	0.01	0.01	0.00
Only index persons	0.01	0.01	0.00
Median age at first event (years)
Whole population	57.18	57.81	55.83
Only index persons	56.18	56.77	54.92

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	49	31	18
Unadjusted period prevalence (%)	0.01	0.01	0.01
Median age at first event (years)	53.71	52.10	56.49

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

No data available

LabWAS

↥

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(3021614) Rheumatoid factor [Units/volume] in Serum or Plasma

5.61

6.69

1.3

35.88

14.76

iu/ml

—

(42870588) Differential panel, method unspecified - Blood

3.00

3.33

7.7

3.3

—

(3013139) Helicobacter pylori Ag [Presence] in Stool

4.40

2.11

1.5

1.0

—

(3012516) Albumin [Mass/volume] in Urine

2.38

2.05

2.9

3.0

2818.87

800.50

mg/l

0.30

(46236952) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD)

3.33

2.04

5.4

2.8

—

59.60

—

(3020682) Albumin/Creatinine [Ratio] in Urine

106

2.10

1.57

4.1

4.0

1.01

10.03

mg/mmol

1.42

(3016251) Hemoglobin.gastrointestinal [Presence] in Stool

3.58

1.56

1.4

2.5

—

(3045414) Leukocytes [Presence] in Urine

3.35

1.47

3.2

2.2

—

(4010399)

2.46

1.46

1.6

1.4

—

(40760892) CBC W Ordered Manual Differential panel - Blood

2.17

1.40

7.6

5.4

—

(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection

3.15

1.39

1.6

1.7

—

(3042936) Bacteria identified in Isolate by Culture

2.13

1.15

1.9

1.4

—

(3017143) Hepatitis C virus Ab [Presence] in Serum

2.38

1.13

2.4

1.3

—

(40761535) Cells panel - Urine sediment

2.23

1.08

3.4

3.6

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

1.95

1.04

3.6

4.9

—

(3000991) Gas panel - Venous blood

0.00

1.01

0.0

6.0

—

(3020460) C reactive protein [Mass/volume] in Serum or Plasma

376

2.17

0.99

15.8

12.6

19.31

24.79

mg/l

0.51

282

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

2.08

0.94

1.5

1.7

—

(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma

2.03

0.93

4.4

6.9

—

(3032080) INR in Blood by Coagulation assay

151

1.68

0.93

4.0

6.9

0.96

1.27

inr

—

(3003694) ABO and Rh group [Type] in Blood

105

0.51

0.85

1.3

—

(3022250) Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction

1.93

0.82

7.3

3.2

235.50

226.91

u/l

—

(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma

147

1.61

0.79

2.9

3.6

18.20

60.13

ng/l

—

107

(3000330) Specific gravity of Urine by Test strip

2.02

0.73

5.0

4.3

—

(3009542) Hematocrit [Volume Fraction] of Blood

330

1.67

0.71

17.6

13.2

38.85

38.63

0.04

215

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

1.73

0.70

1.6

1.7

—

(3030981) Hyaline casts [#/volume] in Urine by Automated count

0.00

0.61

0.0

3.1

—

0.03

—

(3014007) Fractional oxyhemoglobin in Arterial blood

0.00

0.61

0.0

7.1

—

93.81

—

(3021584) Pregnancy associated plasma protein A [Units/volume] in Serum or Plasma

0.00

0.60

0.0

1.5

—

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

1.64

0.59

1.7

1.8

—

(3037467) Urinalysis macro (dipstick) panel - Urine

266

1.45

0.54

6.4

4.0

—

(3021347) Calcium.ionized [Moles/volume] in Serum or Plasma

178

1.43

0.52

4.6

5.2

1.20

1.22

mmol/l

0.66

164

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

159

1.44

0.52

4.0

3.6

—

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

151

1.42

0.49

2.7

1.9

96.80

91.65

pmol/l

0.16

(3007853) Bacteria identified in Skin by Aerobe culture

1.68

0.44

1.6

1.4

—

(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep

1.45

0.44

1.9

1.3

—

(3008909) Norovirus RNA [Presence] in Stool by NAA with probe detection

0.00

0.42

0.0

1.1

—

(3014218) Bicarbonate [Moles/volume] standard in Arterial blood

0.00

0.42

0.0

8.3

—

23.79

—

(3020891) Body temperature

0.00

0.42

0.0

3.6

—

(3023421) Hepatitis B virus surface Ab [Units/volume] in Serum

0.00

0.41

0.0

1.3

—

305.56

—

(3013512) EKG study

108

1.41

0.41

4.7

4.2

—

(40758558) Short blood count panel - Blood

1.42

0.38

10.3

5.6

—

(40761511) CBC panel - Blood by Automated count

401

1.59

0.37

15.8

12.9

—

(3000850) Epithelial cells [#/volume] in Urine

1.42

0.36

3.6

2.7

2.05

3.41

e6/l

0.76

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

218

1.30

0.33

3.4

3.2

—

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

1.34

0.32

2.6

1.4

—

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

1.30

0.29

1.8

1.6

—

(3020059) Calcium [Moles/volume] corrected for albumin in Serum or Plasma

1.23

0.26

1.8

3.4

2.44

2.47

mmol/l

—

(3020564) Creatinine [Moles/volume] in Serum or Plasma

396

1.42

0.25

18.1

15.1

77.29

76.60

umol/l

0.06

396

(3023103) Potassium [Moles/volume] in Serum or Plasma

389

1.33

0.24

17.2

14.9

3.96

mmol/l

0.01

374

(3019550) Sodium [Moles/volume] in Serum or Plasma

391

1.30

0.24

16.8

14.8

139.85

139.88

mmol/l

0.02

377

(3002582) Erythrocytes [#/volume] in Urine

123

0.77

0.24

5.4

3.1

11.26

61.13

e6/l

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

146

1.25

0.23

3.8

4.0

—

(40761536) Microorganisms panel - Urine sediment

1.21

0.22

4.2

3.5

—

(3005033) Fetal Nuchal fold Thickness US

0.00

0.21

0.0

1.2

—

(3043238) Trisomy 21 risk [Likelihood] in Fetus

0.00

0.21

0.0

1.5

—

(3011288) Drugs identified in Urine by Screen method

0.00

0.21

0.0

1.4

—

(3028707) Methadone [Presence] in Urine by Screen method

0.00

0.21

0.0

1.2

—

(1002102) Choriogonadotropin.intact+Beta subunit [Mass/volume] in Serum or Plasma

0.00

0.21

0.0

1.4

—

(3043109) Cytology report of Tissue fine needle aspirate Cyto stain

0.00

0.21

0.0

1.5

—

(3020321) Streptococcus agalactiae [Presence] in Vaginal fluid by Organism specific culture

0.00

0.21

0.0

1.8

—

(3047352) Trisomy 18 risk [Likelihood] in Fetus

0.00

0.21

0.0

1.2

—

(21492888) Glucose tolerance 2 hours gestational panel - Serum or Plasma

0.00

0.21

0.0

1.6

—

(3036489) Thrombin time

0.00

0.21

0.0

1.2

—

20.90

—

(3049207) Fetal Trisomy 21 risk [Likelihood] Based on maternal age

0.00

0.21

0.0

1.3

—

(3019145) Choriogonadotropin.beta subunit free [Mass/volume] in Serum or Plasma

0.00

0.21

0.0

1.6

—

(3027944) Amphetamines [Presence] in Urine

0.00

0.21

0.0

1.3

—

(46235831) Pregnancy associated plasma protein A [Multiple of the median] adjusted in Serum or Plasma

0.00

0.21

0.0

1.2

—

(40763531) Fetal Nuchal fold [Multiple of the median] Thickness adjusted for maternal weight

0.00

0.21

0.0

1.2

—

(3008714) Choriogonadotropin [Multiple of the median] adjusted in Serum or Plasma

0.00

0.21

0.0

1.2

—

(1002224) Polysomnography panel

0.00

0.21

0.0

1.0

—

(3028300) Cannabinoids [Presence] in Urine

0.00

0.21

0.0

1.3

—

(3016879) Cocaine [Presence] in Urine

0.00

0.21

0.0

1.3

—

(3000764) Benzodiazepines [Presence] in Urine

0.00

0.21

0.0

1.3

—

(1001926) Buprenorphine [Presence] in Urine by Screen method

0.00

0.21

0.0

1.2

—

(3027008) Opiates [Presence] in Urine

0.00

0.21

0.0

1.3

—

(40768793) Breast Pathology biopsy report

0.00

0.20

0.0

1.4

—

(40758310) Human epididymis protein 4 [Moles/volume] in Serum or Plasma

0.00

0.20

0.0

1.2

—

797.10

—

(3014162) Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection

0.00

0.20

0.0

1.8

—

(40768804) Tissue Pathology biopsy report

169

1.20

0.18

2.0

2.2

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

0.77

0.17

1.5

1.9

—

(46235355) HIV 1 and 2 tests - Meaningful Use set

1.13

0.17

2.4

1.6

—

(3016771) Amylase [Enzymatic activity/volume] in Serum or Plasma

122

1.21

0.16

2.5

2.1

63.36

54.15

u/l

0.51

115

(1761868) Lipid panel - Serum or Plasma

123

1.19

0.14

2.6

3.6

—

(3023368) Bacteria identified in Blood by Culture

1.20

0.13

4.2

3.6

—

(40768797) Stomach Pathology biopsy report

1.10

0.10

1.0

1.1

—

(3044889) 12 lead EKG panel

256

1.12

0.09

5.6

3.8

—

(3030306) Epithelial cells.non-squamous [#/volume] in Urine by Automated count

0.81

0.09

3.8

2.6

0.68

1.46

e6/l

—

(3007461) Platelets [#/volume] in Blood

421

1.17

0.08

23.6

18.4

253.98

249.46

e9/l

0.18

406

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

140

0.90

0.05

3.1

—

(3026910) Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma

240

0.92

0.04

3.7

2.7

36.78

48.27

u/l

0.84

227

(36304419) Bacteria [Presence] in Urine

108

0.91

0.03

4.5

2.8

—

(3044640) Blood type and Crossmatch panel - Blood

103

1.09

0.02

1.6

2.0

—

(40764999) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)

353

0.97

0.00

13.0

12.4

76.61

79.21

ml/min/173m2

0.35

295

(3041096) Erythrocytes [Presence] in Urine by Automated

114

0.95

0.00

3.7

3.2

—

(3002385) Erythrocyte distribution width [Ratio]

322

0.98

0.00

19.0

16.1

13.81

13.67

0.36

311

(3030467) Casts [#/volume] in Urine by Automated count

112

0.98

0.00

5.1

2.9

0.02

0.44

e6/l

1.68

(3011166) Borrelia burgdorferi Ab [Presence] in Cerebral spinal fluid

0.00

0.0

1.0

—

(3002148) Methylenedioxymethamphetamine [Presence] in Urine by Screen method

0.00

0.0

1.0

—

(1001509) Gas and Carbon monoxide and Electrolytes panel - Arterial blood

0.00

0.0

1.0

—

(3010813) Leukocytes [#/volume] in Blood

423

1.13

0.00

23.6

18.3

7.35

6.66

e9/l

0.88

409

(3027544) Mycobacterium sp identified in Sputum by Organism specific culture

0.00

0.0

3.5

—

(40768800) Prostate Pathology biopsy report

0.00

0.0

1.3

—

(3018559) Microscopic observation [Identifier] in Buccal smear by Cyto stain

0.00

0.0

1.0

—

(3024731) MCV [Entitic volume]

422

1.15

0.00

23.5

18.3

92.17

90.98

0.93

412

(42529200) Cancer Ag 15-3 [Units/volume] in Serum or Plasma by Immunoassay

0.00

0.0

2.8

—

28.12

—

(3011985) Renin [Units/volume] in Plasma

0.00

0.0

1.0

—

25.70

—

(3014148) Varicella zoster virus Ab [Titer] in Serum

0.00

0.0

1.2

—

(3019897) Erythrocyte distribution width [Ratio] by Automated count

0.00

0.0

1.0

—

13.00

—

(3012220) Varicella zoster virus IgM Ab [Presence] in Serum by Immunoassay

0.00

0.0

1.2

—

(3019230) Fractional oxyhemoglobin in Venous blood

0.00

0.0

1.7

—

64.29

—

(40768806) Pleura Pathology biopsy report

0.00

0.0

1.4

—

(40765161) Human bocavirus DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.1

—

(3005988) Vibrio sp identified in Specimen by Organism specific culture

0.00

0.0

1.2

—

(3023183) Ammonium ion [Moles/volume] in Plasma

0.00

0.0

1.9

—

25.14

—

(3030692) Respiratory virus DNA+RNA [Identifier] in Specimen by NAA with probe detection

0.00

0.0

1.2

—

(3043405) Microscopic observation [Identifier] in Specimen by Non-gynecological cytology method

0.00

0.0

1.2

—

(3044290) Cell count panel - Cerebral spinal fluid

0.00

0.0

1.0

—

(3000963) Hemoglobin [Mass/volume] in Blood

422

1.15

0.00

23.8

18.4

132.63

132.87

g/l

0.05

411

(3010380) Borrelia burgdorferi IgG Ab [Units/volume] in Cerebral spinal fluid

0.00

0.0

1.0

—

(3052851) Hemolysis interference index of Serum or Plasma

0.00

0.0

3.0

—

(3025130) Human papilloma virus identified in Specimen

0.00

0.0

1.8

—

(3034770) Mitochondria Ab [Titer] in Serum

0.00

0.0

1.0

—

(3006257) Acetylcholine receptor Ab [Moles/volume] in Serum

0.00

0.0

1.0

—

(4027681)

0.00

0.0

1.4

—

(42868716) Shigella species+EIEC invasion plasmid antigen H ipaH gene [Presence] in Stool by NAA with probe detection

0.00

0.0

1.2

—

(42529201) Cancer Ag 19-9 [Units/volume] in Serum or Plasma by Immunoassay

0.00

0.0

7.7

—

26.67

—

(3000515) Antithrombin actual/normal in Platelet poor plasma by Chromogenic method

0.00

0.0

1.2

—

79.50

—

(3029080) Hemoglobin [Entitic mass] in Reticulocytes

0.00

0.0

2.3

—

29.83

—

(3024522) Salmonella sp identified in Specimen by Organism specific culture

0.00

0.0

1.2

—

(3035941) MCH [Entitic mass]

422

1.15

0.00

23.5

18.2

30.57

30.28

0.49

412

(3012477) Bordetella pertussis DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.0

—

(44816559) Phosphatidylethanol [Mass/volume] in Blood

0.00

0.0

1.4

—

(3016407) Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay

0.00

0.0

1.0

—

3.60

—

(21493466) Plesiomonas shigelloides DNA [Presence] in Stool by NAA with non-probe detection

0.00

0.0

1.2

—

(3018171) Choriogonadotropin [Units/volume] in Serum or Plasma

0.00

0.0

1.2

—

(3019601) Blood group antibody investigation [Interpretation] in Plasma or RBC

0.00

0.0

1.8

—

(36033641) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay

0.00

0.0

3.2

—

(3024928) Oxygen saturation in Venous blood

0.00

0.0

1.7

—

(3011648) Oxygen content in Venous blood

0.00

0.0

1.0

—

12.12

—

(3026361) Erythrocytes [#/volume] in Blood

422

1.15

0.00

23.6

18.3

4.35

4.41

e12/l

0.34

408

(3010838) Calcium [Moles/time] in 24 hour Urine

0.00

0.0

1.4

—

(3019250) Coagulation factor VIII activity actual/normal in Platelet poor plasma by Coagulation assay

0.00

0.0

1.1

—

175.57

—

(3026008) Bacteria identified in Urine by Culture

120

1.00

0.00

6.4

3.1

—

(3005702) Mycobacterium sp identified in Specimen by Organism specific culture

0.00

0.0

1.6

—

(3003434) Protein [Mass/volume] in Pleural fluid

0.00

0.0

1.2

—

35.90

—

(4281824)

0.00

0.0

1.2

—

(3014973) Borrelia burgdorferi IgM Ab [Units/volume] in Cerebral spinal fluid

0.00

0.0

1.0

—

(3003181) Sodium [Moles/volume] in Urine

0.00

0.0

1.3

—

51.13

—

(3012568) Campylobacter sp identified in Specimen by Organism specific culture

0.00

0.0

1.2

—

(3039443) Prostate specific Ag panel - Serum or Plasma

0.00

0.0

1.8

—

(3000924) Streptococcus pyogenes [Presence] in Throat by Organism specific culture

0.00

0.0

1.0

—

(1617658) Protocol used for examination of sentinel lymph nodes

0.00

0.0

1.2

—

Mortality – FinRegistry

↥

Association

Association between endpoint M13_POSTRHEU and mortality.

Females

Parameter	HR [95% CI]	p-value
M13_POSTRHEU	1.159 [0.87, 1.54]	0.311
Birth year	0.989 [0.98, 1.0]	0.013

During the follow-up period (1.1.1998 — 31.12.2019), 52 out of 185 females with M13_POSTRHEU died.

Males

No data

Mortality risk

Mortality risk for people of age

years, who have M13_POSTRHEU.

N-year risk	Females	Males
1	0.088%	No data
5	0.514%	No data
10	1.368%	No data
15	2.583%	No data
20	4.369%	No data

Relationships between endpoints

↥

Index endpoint: M13_POSTRHEU – Chronic postrheumatic arthropathy [Jaccoud]

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Chronic postrheumatic arthropathy [Jaccoud]

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints